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Quantification of Fas protein in CSF of 
patients with neurocysticercosis
Quantificação da proteína Fas no LCR de pacientes com neurocisticercose
José Augusto Camargo, Paulo Henrique Ferreira Bertolucci
Neurocysticercosis (NC) is a term used to define involve-
ment of the central nervous system (CNS) by the larval form 
of the tapeworm Taenia solium. This occurs when humans, 
who are the definitive host of the adult worm, also become 
an intermediate host that harbors the larval form in the 
CNS. NC shows an important incidence in developing coun-
tries, being the disease responsible for approximately 50,000 
deaths every year, although growing migration to developed 
countries is increasing the number of diagnosed cases in 
those countries1. 
Mature cysticerci remain viable in the brain parenchy-
ma for a period of three to six years, a phase during which 
the cysticercus modulates the immune response of the host, 
preventing its own destruction and permitting the peaceful 
coexistence between the parasite and host2,3. In contrast, dur-
ing the degenerative phase, the cysticercus is unable to sup-
press the action of the host immune system and is destroyed. 
The symptoms observed during this phase are generally as-
sociated with the inflammatory response that occurs in NC, 
but also depend on the number, morphological type and lo-
calization of the cysts4-6. Clinical manifestations of cysticer-
cosis include seizures and dementia. Studies suggest that the 
patient remains asymptomatic as along as the cyst continues 
to be viable7,8.
The three evolutive phases of the cysticercus, i.e., viable, 
degenerative and calcified, can be identified by neuroimaging 
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ABSTRACT
Neurocysticercosis is a parasitic disease that affects the central nervous system. The objective of this study was to investigate the correla-
tion between neuronal death evaluated by the quantification of Fas apoptotic factor and the different evolutive forms of neurocysticercosis 
accompanied or not by epileptic seizures. Methods: Cerebrospinal fluid samples from 36 patients with a diagnosis of neurocysticercosis 
divided into the following groups: active cystic form (n=15), 9 patients with and 6 without seizures, and calcified form (=21), 9 with and 12 
without seizures. Fourteen patients comprised the control group. Fas protein concentrations were determined by ELISA. Results: Only the 
group of patients with calcified cysts without seizures presented cerebrospinal fluid levels of Fas similar to those of the control group. Higher 
levels were observed for the other groups. Conclusions: The present finding suggests high cerebrospinal fluid levels of soluble Fas protein, 
except for patients with calcified cysts without seizures. Significant differences were observed for the group with calcified cysts and seizures, 
suggesting greater neuronal damage in these patients. Replacement of the term inactive cyst with reactive inactive cyst is suggested.
Key words: neurocysticercosis, Fas ligand protein, cerebrospinal fluid, neuronal damage.
RESUMO
Neurocisticercose é uma doença parasitária que afeta o sistema nervoso central. O objetivo deste estudo foi investigar a correlação entre 
morte neuronal por meio da quantificação do fator apoptótico Fas e a presença de neurocisticercose nas suas diferentes fases evolutivas, 
acompanhadas ou não de crises epilépticas. Métodos: Foram analisadas amostras de líquido cefalorraquidiano em 36 pacientes com di-
agnóstico de neurocisticercose, determinando-se as concentrações da proteína Fas pelo método ELISA. Foram considerados os seguintes 
grupos: forma cística ativa n=15 (9 com crises, 6 sem crises), forma calcificada n=21 (9 com crises, 12 sem crises) e 14 pacientes (grupo 
controle). Resultados: Apenas o grupo com calcificações sem crises apresentou níveis de Fas semelhantes ao controle. Maiores níveis foram 
observados nos outros grupos. Conclusões: As formas ativa e calcificada apresentam níveis elevados da proteína Fas, exceto para as formas 
calcificadas sem crises. No grupo de calcificações com crise, observamos diferenças mais expressivas, sugerindo maior dano neuronal. 
Sugerimos a substituição da denominação “cisto inativo” por “cisto inativo reagente”.
Palavras-Chave: neurocisticercose, proteína ligante Fas, líquido cefalorraquidiano, dano neuronal.
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methods. In contrast, analysis of cerebrospinal fluid (CSF) 
provides important information about the inflammatory re-
sponse that occurs in NC, permitting a better understanding 
of the interaction between the parasite and host. The clas-
sification of NC lesions into active or inactive based only on 
imaging criteria seems increasingly more inadequate since 
inactive forms detected by imaging exams might present im-
portant clinical and CSF2. 
Recent studies have tried to identify markers able to 
detect brain damage in diseases such as NC9. However, the 
efficacy of these markers seems to be related to clinically 
and laboratory confirmed overtly active disease, with in-
flammatory activity being detected in most cases. A lower 
sensitivity of some markers to certain types of brain le-
sions has also been demonstrated10. A series of biochem-
ical and morphological events lead to cell death, a se-
quence generically called programmed cell death (PCD). 
In contrast to necrotic cell death, PCD is an active process 
in which cells are dying and are removed safely without 
causing inflammation. 
Among the markers of neuronal death, Fas protein has 
been widely studied. Fas belongs to the tumor necrosis fac-
tor (TNF) receptor superfamily and is the main proapoptotic 
protein11. Interaction of the soluble form of Fas protein with 
its receptor (FasL) leads to the formation of a cell death-in-
ducing signaling complex that activates different types of 
caspases, causing mitochondrial damage and, finally, prote-
olytic death12.
The apoptotic process involves the participation of affect-
ed cells in the cascade of self-destruction that culminates in 
the degradation of DNA through the activation of endonu-
cleases, cell disintegration and the formation of “apoptotic 
bodies”13.
Since NC can result in cell death, it would be of clini-
cal importance to determine the type of cell death that 
occurs during the different cystic phases of the disease 
and whether the presence of seizures interferes with the 
pattern of death observed. Therefore, the objective of the 
present study was to quantify soluble Fas protein in CSF 
of patients with active and calcified NC with or without 
epileptic seizures.
METHODS
Patients
All patients included in the study were selected pro-
spectively among patients submitted to CSF puncture as re-
quested by the physician. Patients with NC were diagnosed 
based on a combination of imaging findings [cranial com-
puted tomography (CT) and brain magnetic resonance (MR) 
imaging], CSF alterations, including an immunoenzymatic 
reaction to NC, epidemiological criteria and clinical findings 
according to the criteria of Del Brutto et al.4.
Using the classification suggested by Carpio et al.14, with 
modifications, the patients were divided into the following 
five groups, according to the evolutive phase of the cysticer-
cus in the absence of signs of an inflammatory reaction upon 
imaging and CSF analysis: 
1) Active or viable cysts without seizures (n=6): patients 
presenting one or more cysts in the absence of signs of an 
inflammatory reaction and no seizures.
2) Active or viable cysts with seizures (n=9): patients pre-
senting one or more cysts in the absence of signs of an 
inflammatory reaction and seizures.
3) Inactive or calcified cysts without seizures (n=12): pa-
tients presenting one or more calcified cysts in the 
absence of signs of an inflammatory reaction and no 
seizures.
4) Inactive or calcified cysts with seizures (n=9): patients 
presenting one or more calcified cysts in the absence of 
signs of an inflammatory reaction and seizures.
5) Control group (n=14): patients presenting no neurologi-
cal or systemic alterations who were submitted to lumbar 
puncture for spinal anesthesia due to other reasons, such 
as minor orthopedic surgery or surgery for inguinal her-
nia correction.
All patients with seizures who presented signs of hydro-
cephalus and fever, and whose last seizure episode occurred 
within a period of less than 4 days and more than 60 days 
were excluded from the study.
Patients included in the study who belonged to the 
group with inactive or calcified cysts were submitted to 
CSF puncture for the investigation of possible reinfestation 
with cysticerci associated with symptoms, such as limb par-
esthesia, dizziness, vertigo and tinnitus. These symptoms 
were diagnosed after clinical investigation to be part of os-
teoarticular diseases of the spine and vestibular system dis-
orders. CSF puncture was performed within a period of 4 
to 30 days after the last seizure episode in patients of the 
groups with epileptic seizures. 
All subjects were subjected to CT scan or brain MR. All 
subjects were submitted to lumbar puncture and CSF cyto-
morphological examination.
The project was approved by the Ethics Committee 
of Universidade Federal de São Paulo (UNIFESP, process 
0857/05).
Collection of cerebrospinal fluid samples
CSF samples were collected by the responsible phy-
sician after the patient had signed a free informed con-
sent form according to the guidelines of the Scientific 
Department of the Brazilian Academy of Neurology and 
UNIFESP. With the patient in the sitting position, lum-
bar puncture was performed in the L4/L5 intervertebral 
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space using disposable Quincke needles (23 G x 90 mm or 
22 G x 90 mm) with a short bevel. Samples containing red 
blood cells due to traumatic lumbar puncture were dis-
carded. For the control group, CSF samples were collected 
at the time of lumbar puncture for the surgical procedure 
before injection of the anesthetic. Samples from patients 
with a diagnosis of NC were transported on ice, divided 
into aliquots and frozen at -70ºC until the time for pro-
cessing at the laboratory of the Discipline of Experimental 
Neurology, UNIFESP.
Determination of Fas protein concentration by 
ELISA
The concentration of soluble Fas in CSF of the patients 
was measured by ELISA using the Quantikine kit (R&D 
Systems) according to manufacturer instructions. Briefly, 
100 µL of the CSF sample or different concentrations of re-
combinant human soluble Fas provided for construction of 
the standard curve (62.5, 125, 250, 500, 1000, 2000 pg/mL) 
were diluted in reaction buffer and incubated in duplicate 
for two hours at room temperature. The wells were washed 
three times with phosphate-buffered saline, and the bioti-
nylated secondary antibody against human soluble Fas 
(50 ng/mL) was added. The plates were incubated for two 
hours at room temperature. After repeated washes ( four 
times), the samples were incubated with HRP-conjugated 
streptavidin for 30 minutes. Bound antigen was detected 
by incubation with tetramethylbenzidine for 30 minutes. 
The reaction was stopped by the addition of 2 N sulfuric 
acid as blocking buffer. Optical densities were read at 450 
nm over the first 30 minutes, with correction at 540 and 
570 nm.
Statistical analysis
Fas concentrations were analyzed by the t-test for 
independent samples. ANOVA or the F test was used to 
compare all groups as a whole. If a significant difference 
was detected (p<0.05), multiple comparisons were per-
formed to determine between which groups the difference 
occurred.
RESULTS
Fifty patients (27 men and 23 women) ranging in age from 
19 to 59 years were studied. The mean age was 38.8 years 
(standard deviation 8.5).
The samples were classified into active cysts, calci-
fied cysts and controls, and the groups were then sub-
divided into patients with and without seizures. All pa-
tients were submitted to cranial CT or MR in order to 
be included in the study. The CT or MR images and CSF 
analysis, consisting of cytomorphological examination, 
protein quantification, electrophoresis, glucose and 
chloride measurement, revealed no signs of an inflam-
matory reaction in any of the patients. All patients of the 
group with active cysts presented multiple intraparen-
chymatous cysts, eight patients of the group with calci-
fied cysts presented single intraparenchymatous calcifi-
cation (three of the group with seizures and five of the 
group without seizures) and the remaining patients pre-
sented multiple calcified cysts. Images showing the pres-
ence of 6 to 100 cysts were defined as multiple cysts and 
classified as moderate infestation according to García 
et al.15. Among the four groups with NC studied, only 
the group of patients with calcified cysts without sei-
zures presented CSF levels of Fas similar to those of the 
control group. Higher levels were observed in the oth-
er groups, but statistical analysis only revealed a signif-
icant difference when patients with calcified cysts and 
seizures were compared to the control group and to the 
group with calcified cysts without seizures, and when 
the latter was compared to the group with viable cysts 
without seizures. The percent increase in CSF levels of 
Fas was 36% (p=0.01), 55% (p=0.038) and 85% (p=0.011) 
in the groups of patients with active cysts without sei-
zures, active cysts with seizures and calcified cysts with 
seizures, respectively, when compared individually to the 
control group.
In the group with calcified cysts, all patients were from 
rural areas, and no significant differences in CSF Fas lev-
els were observed between patients with single and mul-
tiple intraparenchymatous calcification. The average nor-
mal reference value of Fas obtained for the control group 
by the immunoenzymatic method was 208.00 pg/mL. In 
contrast, an increase of Fas concentrations compared to 
the control group was observed in patients with viable 
and calcified cysts, except for the group of calcifications 
without seizures, as well as in patients of the same group 
with seizures compared to those without seizures (Table). 
This finding suggests the occurrence of apoptotic activ-
ity accompanied by neuronal death in the two groups. 
However, a significant difference was only observed when 
the group of calcified cysts with seizures was compared to 
the control group and to the group of calcified cysts with-
out seizures. 
Table. Quantification of soluble Fas protein in the CSF of the 
different groups studied.
Fas concentration (pg/mL) Mean Standard deviation
Standard 
error
Control 208.00 51.24 13.70
Active cysts with seizures 322.75 137.05 45.68
Active cysts without seizures 283.11 57.53 23.49
Calcification with seizures 385.09 162.39 54.13
Calcification without seizures 193.17 56.24 16.23
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DISCUSSION
Apoptosis participates in various vital physiological pro-
cesses, such as embryo development, involution of the mam-
mary gland after breast-feeding, control of tumor cell prolifer-
ation and regulation of immune cell populations. Mutations 
in genes that trigger the apoptotic process are the cause of 
different diseases16,17. Since cell death is essential for life, it 
should follow a meticulous program. Any disturbance in this 
process, i.e., excessive or deficient death of cells, can cause a 
variety of diseases18. Excessive apoptosis may lead to neuro-
degenerative diseases (Alzheimer’s and Parkinson’s disease), 
secondary lesions after ischemia and osteoporosis, and can 
actively participate in parasitic diseases such as NC19. In the 
present study, the Fas levels observed in the two cystic forms 
of NC (active and calcified), except for calcified cysts with-
out seizures, might be related to the activation of proapop-
tic cascades in neighboring neuronal cells as a reaction to 
these structures. The main clinical manifestations of NCC 
are epileptic seizures. These manifestations are directly asso-
ciated with altered synaptic transmission, which results from 
changes in the concentrations of amino acid neurotransmit-
ters in the CNS.
Numerous studies have measured Fas protein levels in 
blood of patients with different neoplastic, infectious, autoim-
mune and degenerative diseases, whereas studies discussing 
Fas measurement in CSF are scarce20. Elevated Fas levels are 
observed in patients in the advanced phase of diseases com-
pared to those in the early stage. Mogi et al.21 found elevated 
tissue and CSF concentrations of soluble Fas in nigrostriatal 
dopaminergic neurons of patients with Parkinson’s disease 
compared to the control group. Ciusani et al.22 investigated 
soluble Fas levels in CSF of patients with multiple sclerosis 
compared to patients with other types of neurological diseases 
and healthy controls. The authors concluded that the partici-
pation of soluble Fas in the pathogenesis of multiple sclerosis 
suggests that a lower rate of apoptosis in CSF might be a char-
acteristic of the disease, thus demonstrating the importance 
of Fas protein for the detection of neurological diseases, espe-
cially those related to dementia. In this respect, Zhou et al.23 
quantified soluble Fas levels in blood and CSF of patients with 
multiple sclerosis. Analysis of the two types of samples showed 
significantly elevated soluble Fas levels in patients in the active 
phase of disease compared to those in the inactive phase and 
to the control group. Martínez et al.24 evaluated CSF concen-
trations of soluble Fas and interleukin 6 (IL-6) in ten patients 
with dementia of the Alzheimer type and ten control subjects, 
and detected a significant increase in soluble Fas and IL-6 
concentrations in dementia patients compared to the control 
group and non-dementia patients. Felderhoff-Mueser et al.25 
observed high concentrations of soluble Fas in children with 
hydrocephalus, whereas the control group presented levels be-
low the detection limit. Towfighi et al.26 concluded that soluble 
Fas concentration is elevated in CSF of patients with HIV who 
present symptoms of dementia and it is correlated with the se-
verity of the condition.
In the study of Owen-Schaub et al.27, elevated blood lev-
els of soluble Fas in patients with melanoma were correlated 
with a poor prognosis and lower survival. This marker was 
found to be useful for the evaluation of disease progression 
and for the establishment of therapeutic strategies. In most 
studies, blood levels of Fas are compared between patients 
with diseases and control groups or patients without disease 
with normal reference values, being defined in different pro-
tocols such as that of the R&D Systems kit used in this study. 
However, normal reference values of Fas in CSF need to be 
established for patients without disease. CSF levels of Fas are 
generally compared between the early and advanced stages 
of the same disease.
In view of the results obtained, discussion of the term “in-
active cyst” proposed by Sotelo et al.28 and Carpio et al.14, with 
modifications, is necessary. We often observe that patients 
with calcified NC, or even physicians and healthcare profes-
sionals who are not familiar with the disease, falsely assume 
that the disease is resolved, harmless or cured, and will not re-
sult in further damage when analyzing the reports or results of 
imaging exams (CT and MR) containing the expression “inac-
tive cyst”. Although referring to the state of the parasite, modi-
fication of this classification is of the utmost importance since 
brain tissue containing calcified cysts29. We therefore propose 
replacement of the term “inactive cyst” with “reactive inactive 
cyst” to indicate the presence of a substance resulting from the 
death of a cysticercus that provokes a reaction. 
The present results led us to conclude that an increase in 
CSF levels of Fas in patients with calcified and viable cysts 
presenting seizures and in patients with viable cysts with-
out seizures indicates the presence of apoptosis in the brain 
parenchyma. For patients with calcified cysts, no significant 
differences in CSF Fas levels were observed between those 
presenting single and multiple intraparenchymatous calcifi-
cation. One conclusion that can be drawn is that the pres-
ence of elevated CSF levels of Fas reflects the occurrence of 
neuronal injury and death due to active apoptosis.
 Further studies are necessary to better understand the 
signaling pathways involved in apoptosis whose participants 
are proteins encoded by specific genes involved in the pro-
cess of apoptosis. In this respect, the morphological and bio-
chemical aspects of cell death due to apoptosis in different 
diseases, including NC, need to be better investigated.
Despite the absence of inflammatory signs in the imaging 
exams and CSF of patients with NC, a dynamic metabolic and 
inflammatory reaction might occur in the brain parenchyma. 
The present results emphasize the importance of considering 
NC as a progressive and active disease, even when the cysts 
are in the calcified phase. Replacement of the term “inactive 
cyst” with “reactive inactive cyst” is suggested.
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